IFNG and myeloid sarcoma: It has been reported that its systemic administration worsen the original MS disease; its increased production has been described before MS exacerbations; it has been found in lesions in patients with MS; it is thought to induce oligodendrocyte death by apoptosis; MS patients have been shown to have an increased number of mononuclear IFN-γ secreting cells, as well as a significantly increased level of IFN-γ mRNA-expressing mononuclear cells (both in blood and cerebrospinal fluid) [5].